A Phase 2/3 trial of PTG-100 in chronic pouchitis
Phase of Trial: Phase II/III
Latest Information Update: 26 Mar 2018
Price : $35 *
At a glance
- Drugs PTG 100 (Primary)
- Indications Pouchitis
- Focus Therapeutic Use
- 26 Mar 2018 According to a Protagonist Therapeutics media release, based on the interim results (n=65) of the ulcerative colitis PROPEL study which are reviewed by independent Data Monitoring Committee (DMC), company has postponed the decision to initiate this Phase 2/3 study. PROPEL study has been discontinued by DMC.
- 13 Mar 2018 New trial record
- 07 Mar 2018 According to a Protagonist Therapeutics media release, the company will initiate this trial in 2018 pending a positive decision from the interim futility analysis in the ulcerative colitis PROPEL study.